Register entry
- Registered sites
- 3
- Active NDC listings
- 2
- Labeller names
- 2
- Live patents
- 0
- Countries
- 3
- Base
- Australia
Authorisation
Registered operations
Analytical testing3Labelling1Finished drug manufacture3Packaging1
Sites
Registered establishments
3| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Seqirus Pty LtdRegistrant: Seqirus, Inc. | 63 Poplar Road, Parkville, Victoria 3052, Australia (AUS) | Analytical testing, Finished drug manufacture | 3002806753747286735 |
| Seqirus Vaccines LimitedRegistrant: Seqirus, Inc. | Gaskill Road, Liverpool, Speke L24 9GR, United Kingdom (GBR) | Analytical testing, Finished drug manufacture | 3002806949233657951 |
| Seqirus IncRegistrant: Seqirus, Inc. | 475 Green Oaks Parkway, Holly Springs, North Carolina (NC) 27540, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3007867647080102141 |
Catalogue
Drug listings by form and route
22 active NDC listings: 2 vaccine. By marketing category: BLA 2.
| Dosage form | NDCs |
|---|---|
| injection, suspension | 2 |
| Route | NDCs |
|---|---|
| intramuscular | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| seqirus inc. | 1 |
| seqirus, inc. | 1 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| FLUAD | INFLUENZA A VIRUS A/Missouri/11/2025 IVR-279 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/Michigan/105/2025 IVR-285 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/Tokyo/EIS13-175/2025 ANTIGEN (FORMALDEHYDE INACTIVATED) | injection, suspension, intramuscular | 70461-026BLA |
| Flucelvax | INFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) | injection, suspension, intramuscular | 70461-656BLA |
Neighbours
Registered in the same town
4- AstraZeneca PLCLiverpool, GBR
- FUJIFILM CorporationHolly Springs, NC
- Vantive US Healthcare LLCLiverpool, GBR
- Ames Goldsmith CorpLIVERPOOL, GBR
Compare
Comparable companies in Australia
- Eurofins BioPharma Product Testing Australia Pty Ltd2 sites · 0 NDC
- Mayne Pharma International Pty Ltd.1 site · 64 NDC
- VEGANIC SKN LIMITED1 site · 49 NDC
- Martin Pleasance Pty Ltd1 site · 30 NDC
- ADVANCE ZINCTEK LIMITED1 site · 6 NDC
- RATIONALE GROUP PTY LTD1 site · 4 NDC
- WILD CHILD LABORATORIES PTY LTD1 site · 2 NDC
- ANSTO1 site · 1 NDC
Enquiry
Common questions
- Is Seqirus, Inc. FDA approved?
- Seqirus, Inc. holds 3 FDA-registered establishments across 3 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Seqirus, Inc.'s drugs manufactured?
- At registered sites in Australia, the United Kingdom, the United States. The FDA register lists Parkville; Liverpool; Holly Springs, NC. Registered operations: analytical testing, labelling, finished drug manufacture, packaging.
- What drugs does Seqirus, Inc. make?
- 2 products are listed under Seqirus, Inc. in the openFDA NDC Directory, most often as injection, suspension. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.